Endocrine Abstracts

Aims & objectives: IMPROVE™ is a 6-month, multi-national, prospective, observational study, assessing the safety and efficacy of biphasic insulin aspart 30/70 (BiAsp 30) in patients with type 2 diabetes.Methods: We present the efficacy data from the Indian cohort of IMPROVE study. A total of 17 995 subjects entered the study and 16 942 subjects completed the study. BiAsp 30 was initiated and dose was adjusted at the physician’s discretion, ...